STShi Hua Tan

Shi Hua Tan

*This is an algorithmically generated author record based on publicly available information.

Shi Hua Tan has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Lei Ye

    Department of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, AL 35255, USA

    2 shared publications
  • Chang Yan

    College of Materials Science and Engineering, Hunan University, Changsha, China 410072

    1 shared publication
  • Chixuan Liu

    A*STAR Skin Research Laboratories (A*SRL), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, #06-06 Immunos, Singapore 138648, Republic of Singapore

    1 shared publication
  • Hui Zheng

    College of Materials Science and Engineering, Hunan University, Changsha, China 410072

    1 shared publication
  • Kun Liang

    Lee Kong Chian School of Medicine Nanyang Technological University (NTU) Singapore Republic of Singapore

    1 shared publication
  • Liping Su

    National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore

    1 shared publication

Latest Publications

  • Open Access

    Ultrasound-activated piezoelectric hydrogel scaffold for synergistic immunomodulation and angiogenesis in accelerated wound healing

    by Pengfei Yan, Hui Zheng, Peng Liu, Chang Yan, Mengqi Zhao, Sida Ling, Zuyong Wang, Chixuan Liu, Shi Hua Tan, Kun Liang, et al.


  • Open Access

    Non-viral vector based gene transfection with human induced pluripotent stem cells derived cardiomyocytes

    by Shihua Tan, Zhonghao Tao, Szejie Loo, Liping Su, Xin Chen, Lei Ye

    Non-viral transfection of mammalian cardiomyocytes (CMs) is challenging. The current study aims to characterize and determine the non-viral vector based gene transfection efficiency with human induced pluripotent stem cells (hiPSCs) derived cardiomyocytes (hiPSC-CMs). hiPSC-CMs differentiated from PCBC hiPSCs were used as a cell model to be transfected with plasmids carrying green fluorescence protein (pGFP) using polyethylenimine (PEI), including Transporter 5 Transfection Reagent (TR5) and PEI25, and liposome, including lipofectamine-2000 (Lipo2K), lipofectamine-3000 (Lipo3K), and Lipofectamine STEM (LipoSTEM). The gene transfection efficiency and cell viability were quantified by flow cytometry. We found that the highest gene transfection efficiency in hiPSC-CMs on day 14 of contraction can be achieved by LipoSTEM which was about 32.5 ± 6.7%. However, it also cuased poor cell viability (60.1 ± 4.5%). Furthermore, a prolonged culture of (transfection on day 23 of contraction) hiPSC-CMs not only improved gene transfection (54.5 ± 8.9%), but also enhanced cell viability (74 ± 4.9%) by LipoSTEM. Based on this optimized gene transfection condition, the highest gene transfection efficiency was 55.6 ± 7.8% or 34.1 ± 4%, respectively, for P1C1 or DP3 hiPSC line that was derived from healthy donor (P1C1) or patient with diabetes (DP3). The cell viability was 80.8 ± 5.2% or 92.9 ± 2.24%, respectively, for P1C1 or DP3. LipoSTEM is a better non-viral vector for gene transfection of hiPSC-CMs. The highest pGFP gene transfection efficiency can reach >50% for normal hiPSC-CMs or >30% for diabetic hiPSC-CMs.


  • Stem Cell Homing: a Potential Therapeutic Strategy Unproven for Treatment of Myocardial Injury

    by Zhonghao Tao, Shihua Tan, Wen Chen, Xin Chen

    Despite advances in the prevention and therapeutic modalities of ischemic heart disease, morbidity and mortality post-infarction heart failure remain big challenges in modern society. Stem cell therapy is emerging as a promising therapeutic strategy. Stem cell homing, the ability of stem cells to find their destination, is receiving more attention. Identification of specific cues and understanding the signaling pathways that direct stem cells to targeted destination will improve stem cell homing efficiency. This review discusses the cellular and molecular mechanism of stem cell homing at length in the light of literature and analyzes the problem and considerations of this approach as a treatment strategy for the treatment of ischemic heart disease clinically.


  • Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes: a Critical Step for Drug Development and Cell Therapy

    by Shi Hua Tan, Lei Ye

    Cardiomyocytes derived from human pluripotent stem cells (hPSCs) are emerging as an invaluable alternative to primarily sourced cardiomyocytes. The potentially unlimited number of hPSC-derived cardiomyocytes (hPSC-CMs) that may be obtained in vitro facilitates high-throughput applications like cell transplantation for myocardial repair, cardiotoxicity testing during drug development, and patient-specific disease modeling. Despite promising progress in these areas, a major disadvantage that limits the use of hPSC-CMs is their immaturity. Improvements to the maturity of hPSC-CMs are necessary to capture physiologically relevant responses. Herein, we review and discuss the different maturation strategies undertaken by others to improve the morphology, contractility, electrophysiology, and metabolism of these derived cardiomyocytes.